Cyclosporine Plus Isotretinoin for Darier Disease: A Preliminary Observation in Three Patients.
- 1Institute of Dermatology, Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China.
- 2Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong, People's Republic of China.
Abstract
Darier disease (DD) is a chronic disorder of keratinization characterized by pruritic keratotic papules and plaques in seborrheic areas, for which effective treatment options remain limited. To describe the preliminary outcomes of combination therapy with cyclosporine and isotretinoin, we retrospectively reviewed the medical records of three patients with clinically and histopathologically confirmed DD. Outcomes included changes in cutaneous lesions, pruritus visual analog scale (VAS) scores, and Dermatology Life Quality Index (DLQI) scores, as well as adverse events, laboratory findings, and the post-treatment clinical course. All three patients showed clinical improvement in cutaneous lesions and pruritus, with reductions of 6-7 points in pruritus VAS scores and 10-14 points in DLQI scores from baseline to treatment completion. After treatment discontinuation, no clinically apparent relapse occurred during follow-up periods of 9, 4, and 3 months in Cases 1, 2, and 3, respectively. Mild adverse events included cheilitis, alopecia, and xerosis; transient mild laboratory abnormalities were also observed, and no serious adverse events occurred. In this small retrospective case series, cyclosporine plus isotretinoin was associated with clinical improvement and acceptable short-term tolerability. Larger studies with longer follow-up are needed to evaluate the efficacy and safety of this combination.
Related
- Acne therapy with isotretinoin is well tolerated in patients with established inflammatory bowel disease: a retrospective, single center study.
- A pilot study of invasive vagus nerve stimulation in Chinese patients with Alzheimer’s disease: preliminary results on safety, cognition, and biomarkers
- P4-ATPase BbCrpa2 detoxifies cyclosporine a via AP2-clathrin-dependent endocytic pathway in Beauveria bassiana
- Combining pro-resolving therapy with cyclosporine A restores immune homeostasis and reduces toxicity in autoimmune bone marrow failure
- Oenological Characterization of Divona, a New Disease-Resistant Variety, and Preliminary Insights into the Influence of Maceration and Fermentation Temperature Across Three Vintages.
BibTeX
@article{shu2026cyclosporine,
title = {{Cyclosporine Plus Isotretinoin for Darier Disease: A Preliminary Observation in Three Patients.}},
author = {Zhirong Shu and Yu Jiang and Tingnan Chen and Shilin Deng and Xiaohong Lin and Jingyao Liang and Xibao Zhang},
journal = {Clinical, cosmetic and investigational dermatology},
year = {2026},
month = oct,
doi = {10.2147/ccid.s643738},
url = {https://europepmc.org/article/MED/42959309},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Cyclosporine Plus Isotretinoin for Darier Disease: A Preliminary Observation in Three Patients.
AU - Zhirong Shu
AU - Yu Jiang
AU - Tingnan Chen
AU - Shilin Deng
AU - Xiaohong Lin
AU - Jingyao Liang
AU - Xibao Zhang
PY - 2026
DA - 2026/10/24
JO - Clinical, cosmetic and investigational dermatology
DO - 10.2147/ccid.s643738
UR - https://europepmc.org/article/MED/42959309
AB - Darier disease (DD) is a chronic disorder of keratinization characterized by pruritic keratotic papules and plaques in seborrheic areas, for which effective treatment options remain limited. To describe the preliminary outcomes of combination therapy with cyclosporine and isotretinoin, we retrospectively reviewed the medical records of three patients with clinically and histopathologically confirmed DD. Outcomes included changes in cutaneous lesions, pruritus visual analog scale (VAS) scores, and Dermatology Life Quality Index (DLQI) scores, as well as adverse events, laboratory findings, and the post-treatment clinical course. All three patients showed clinical improvement in cutaneous lesions and pruritus, with reductions of 6-7 points in pruritus VAS scores and 10-14 points in DLQI scores from baseline to treatment completion. After treatment discontinuation, no clinically apparent relapse occurred during follow-up periods of 9, 4, and 3 months in Cases 1, 2, and 3, respectively. Mild adverse events included cheilitis, alopecia, and xerosis; transient mild laboratory abnormalities were also observed, and no serious adverse events occurred. In this small retrospective case series, cyclosporine plus isotretinoin was associated with clinical improvement and acceptable short-term tolerability. Larger studies with longer follow-up are needed to evaluate the efficacy and safety of this combination.
SN - 1178-7015
ER -